A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD)

Description

The main objective of this study is to evaluate the safety, efficacy and pharmacokinetics of paricalcitol oral solution in pediatric participants of ages 0 to 9 years with SHPT associated with stage 5 CKD receiving Peritoneal Dialysis (PD) or Hemodialysis (HD). The 24-week study is divided into two 12-week dosing periods (Dosing Period 1 followed by Dosing Period 2).

Conditions

Chronic Kidney Disease (CKD), Secondary Hyperparathyroidism (SHPT)

Talk to us

Study Overview

On this page

Study Details

Study overview

The main objective of this study is to evaluate the safety, efficacy and pharmacokinetics of paricalcitol oral solution in pediatric participants of ages 0 to 9 years with SHPT associated with stage 5 CKD receiving Peritoneal Dialysis (PD) or Hemodialysis (HD). The 24-week study is divided into two 12-week dosing periods (Dosing Period 1 followed by Dosing Period 2).

A Phase 3, Prospective, Open-Label, Multicenter Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Paricalcitol Oral Solution for the Treatment of Secondary Hyperparathyroidism in Pediatric Subjects Ages 0 to 9 Years With Stage 5 Chronic Kidney Disease Receiving Peritoneal Dialysis or Hemodialysis

A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD)

Condition
Chronic Kidney Disease (CKD)
Intervention / Treatment

-

Contacts and Locations

Little Rock

Arkansas Children's Hospital /ID# 225417, Little Rock, Arkansas, United States, 72202

Redwood City

Stanford University /ID# 252150, Redwood City, California, United States, 94063

Washington

Children's National Medical Center /ID# 225991, Washington, District of Columbia, United States, 20010-2916

Miami

Holtz Childrens Hospital, University of Miami /ID# 225636, Miami, Florida, United States, 33136-1005

Miami

Nicklaus Children's Hospital /ID# 210517, Miami, Florida, United States, 33155-3009

Atlanta

Emory University /ID# 140665, Atlanta, Georgia, United States, 30322-1014

Boston

Boston Children's Hospital /ID# 162863, Boston, Massachusetts, United States, 02115

Charlotte

Duplicate_Levine Children's Specialty Center- Charlotte /ID# 216057, Charlotte, North Carolina, United States, 28203-5866

Philadelphia

Children's Hospital of Philadelphia - Main /ID# 213802, Philadelphia, Pennsylvania, United States, 19104-4319

Dallas

University of Texas Southwestern Medical Center /ID# 210495, Dallas, Texas, United States, 75390-7208

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Participant is currently diagnosed with and/or being treated for secondary hyperparathyroidism (SHPT).
  • * Participant must be diagnosed with chronic kidney disease (CKD) stage 5 receiving peritoneal dialysis (PD) or hemodialysis (HD) for at least 30 days prior to initial Screening.
  • * For entry into the Washout Period (for vitamin D receptor activator \[VDRA\] non-naive participants), the participant must meet the appropriate laboratory criteria based upon the participant's age as described in the protocol.
  • * For entry into the Dosing Period (for VDRA-naive participants or VDRA non-naive participants who have completed the Washout Period), the participant must meet the appropriate laboratory criteria based upon the participant's age as described in the protocol.
  • * Participant is scheduled to receive a living donor kidney transplant within 3 months of Screening or is a kidney transplant recipient.
  • * Participant is expected to discontinue peritoneal dialysis (PD) or hemodialysis (HD) within 3 months of the initial Screening visit.
  • * Participant has had a parathyroidectomy within 12 weeks prior to Screening.
  • * Participant is taking maintenance calcitonin, bisphosphonates, glucocorticoids (in a dose equivalent to more than \> 0.16 mg/kg/day or 5 mg prednisone/day, whichever is lower), 4 weeks prior to Dosing.
  • * Participant is receiving calcimimetics at the time of Screening or is expected to initiate calcimimetics at any time throughout the study.
  • * Participant is unable to take oral medications.

Ages Eligible for Study

0 Years to 9 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

AbbVie,

ABBVIE INC., STUDY_DIRECTOR, AbbVie

Study Record Dates

2026-10-30